Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its fiscal third-quarter results later this week. Experts are anticipating strong results driven by the robust sales of Lilly's blockbuster treatments, particularly the diabetes franchise. However, there are also concerns about potential headwin